Profund Advisors LLC lifted its stake in shares of NetApp Inc. (NASDAQ:NTAP) by 14.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,660 shares of the data storage provider’s stock after purchasing
Millions of seniors rely on Medicare to provide health coverage in retirement. But more than half of Gen Xers today aren't confident that Medicare will do the trick once they become eligible, according to new data from Ameriprise Financial. Consequently, many workers who are midway through their
May 17, 2018: Here are four stocks trading with heavy volume among 57 equities making new 52-week lows in Thursday’s session. On the NYSE advancers led decliners by about 1.12 to 1 and on the Nasdaq, advancers led decliners by about 1.5 to 1.
Celgene Corp. (NASDAQ: CELG) dropped about 2.7% Thursday to post a new 52-week low of $79.16. Shares closed at $81.36 on Wednesday and the stock’s....More>>>
The trade fight between the U.S. and China is starting to have an effect, but possibly not where President Donald Trump intended when he imposed extra tariffs on steel and aluminum imports.
Pork prices in Tokyo fell in April from a year earlier, and that subtracted 0.04 percentage point from inflation, one of the biggest causes of a weaker-than-expected price rise. China imposed extra 25....More>>>
Equities research analysts predict that MDC Partners (NASDAQ:MDCA) will post ($0.07) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for MDC Partners’ earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.11). MDC Partners reported earnings per share of ($0.21) in the same....More>>>
“Wanna get away?” The catchy Southwest Airlines Co (NYSE:LUV) slogan perfectly matches the mood at Tesla Inc (NASDAQ:TSLA). Long Wall Street’s poster child, TSLA stock is recently giving even the most hardened bulls some pause. Although company shares are up a meteoric 50% year-to-date, it has been less impressive after loosely flirting with the $400 mark.
In the same way that prioritizing growth typically means taking on more risk in pursuit of greater returns, investing in companies at early stages of their development means embracing greater uncertainty. More well-established growth stocks have their advantages — among them, a wider breadth of available business information and a tendency toward more-predictable performance — buta strict....More>>>
The short interest data are out for the most recent settlement date, April 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies.....More>>>
bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.
Bluebird results: The only number that really matters
Westpac Banking Corp raised its stake in Edwards Lifesciences (NYSE:EW) by 22.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 67,689 shares of the medical research company’s stock after purchasing an additional 12,500 shares during the period. Westpac Banking Corp’s holdings in Edwards Lifesciences were worth $9,444,000 as of its most recent SEC....More>>>
U.S. stock futures are trading broadly lower this morning. Wall Street was clearly anxious ahead of this morning’s April jobs report. Expectations were for a gain of 188,000 last month, on the heels of March’s surprisingly low 108,000 job adds.
Meanwhile, corporate earnings continue to chug along. Alibaba Group Holding Ltd (NYSE:BABA), Celgene Inc. (NASDAQ:CELG) and GoPro Inc.....More>>>
Geron (GERN) is a tiny biotech, <$1 billion market cap, with an oversized history and an undersized pipeline. Its CEO has managed to steer the company through the wilderness within clear sight of the promised land. He expects that by Q3 2018, Johnson & Johnson’s (JNJ) subsidiary Janssen will make a long-awaited continuation decision as to whether it will proceed with development of....More>>>
NanoString Technologies (NASDAQ: NSTG) is one of 91 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare NanoString Technologies to related businesses based on the strength of its earnings, p
Geron Corporation (NASDAQ:GERN), a clinical-stage cancer company, has grabbed the attention of growth investors due to its enormous upside potential. The short version of the story is that Geron is awaiting a critical continuation decision by partner Johnson & Johnson (NYSE:JNJ) in regards t
The average stock in the Nasdaq 100 is up just over 3% year to date. Using snapshots from our popular Trend Analyzer tool, below is a look at the best and worst performing stocks in the Nasdaq 100 so far in 2018.
At the top of the list is Netflix (NASDAQ:NFLX) with a year-to-date gain of
Celgene (CELG) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. The c
To stave off generic competition drug makers often get creative. They seek new uses for old drugs, seek patent extensions and refuse to provide samples to generic rivals. Allergan (AGN) even sold Restasis (dry eye) patents to the St. Regis Mohawks in order to rent their sov